Resumen de acción AVDL
Avadel Pharmaceuticals plc opera como empresa biofarmacéutica en Estados Unidos.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Competidores de Avadel Pharmaceuticals plc
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.30 |
| 52 Week High | US$19.04 |
| 52 Week Low | US$15.74 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 7.65% |
Noticias y actualizaciones recientes
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Recent updates
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16
Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?
Aug 01Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?
May 03Avadel Pharmaceuticals filed for 500M mixed shelf offering
Aug 31Avadel Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023
Jun 29Avadel: Further Delay, But Some Light At The End Of The Tunnel
Jun 16Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness
Mar 21Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Mar 15Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Nov 19Avadel Pharmaceuticals: I Am Holding
Nov 01Avadel Pharmaceuticals, The Jazz-Killer
Aug 05Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jul 23Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy
Jun 09Avadel Pharmaceuticals EPS beats by $0.09
May 10Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021
Mar 11Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?
Feb 05
Avadel Pharmaceuticals' (NASDAQ:AVDL) Stock Price Has Reduced 35% In The Past Three Years
Jan 10Avadel files US application for its lead drug
Dec 16Avadel's Xyrem Competitor: A Quick Overview
Dec 15Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Dec 15Rentabilidad de los accionistas
| AVDL | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 2.7% | 3.0% | 0.3% |
| 1Y | n/a | 12.0% | 24.2% |
Rentabilidad vs. Industria: Datos insuficientes para determinar los resultados de AVDL en comparación con el sector US Pharmaceuticals .
Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de AVDL frente al mercado US.
Volatilidad de los precios
| AVDL volatility | |
|---|---|
| AVDL Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: AVDL no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de AVDL en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2015 | 154 | Greg Divis | www.avadel.com |
Avadel Pharmaceuticals plc opera como empresa biofarmacéutica en Estados Unidos. Su principal producto candidato es LUMRYZ, una formulación de oxibato de sodio, que se encuentra en un ensayo clínico de fase 3 para el tratamiento de la somnolencia diurna excesiva o cataplejía en adultos con narcolepsia. La empresa era conocida anteriormente como Flamel Technologies SA y cambió su nombre a Avadel Pharmaceuticals plc en enero de 2017.
Resumen de fundamentos de Avadel Pharmaceuticals plc
| Estadísticas fundamentales de AVDL | |
|---|---|
| Capitalización bursátil | US$1.66b |
| Beneficios(TTM) | -US$160.28m |
| Ingresos (TTM) | US$27.96m |
59.3x
Ratio precio-ventas (PS)-10.3x
Ratio precio-beneficio (PE)¿Está AVDL sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de AVDL | |
|---|---|
| Ingresos | US$27.96m |
| Coste de los ingresos | US$846.00k |
| Beneficio bruto | US$27.12m |
| Otros gastos | US$187.39m |
| Beneficios | -US$160.28m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
May 08, 2024
| Beneficios por acción (BPA) | -1.77 |
| Margen bruto | 96.97% |
| Margen de beneficio neto | -573.17% |
| Ratio deuda/patrimonio | 37.3% |
¿Cómo se ha desempeñado AVDL a largo plazo?
Ver rendimiento histórico y comparativa